VELARU GALACTIC EXHIBIT PACK — PHARMA / CLINICAL TRIALS
Jurisdiction: Switzerland (ch)
Modality: Text / Chat
Program: Velaru Pharma / Clinical Trials · Switzerland (galactic_pharma_ch)
Product ID: pharma:ch:bundle:text
Vertical: pharma
Generated: 2026-08-15T11:46:48.423319Z
Authority: Switzerland FINMA AI Pack — 21 CFR Part 11 Clinical AI Audit Pack
Deadline: FADP revised + FINMA AI expectations
Velaru verify: https://velaru.onrender.com/verify

EXHIBIT A — AI INVENTORY
[
  {
    "named_entity": "Velari",
    "slug": "velari",
    "ai_use_case": "AI-assisted Pharma / Clinical Trials decisions",
    "vertical": "pharma",
    "risk_tier": "elevated",
    "external_validation": "Velaru independent receipt verification",
    "handler_receipt_lock": "https://velaru.onrender.com/r/4c58eac890bfd031ce2189de5a1ca9ea292a0c837f5f535daf164aef34f31e53",
    "compliance_state": "grace_period",
    "asymmetry_grade": "A",
    "found_scripture_export": "https://velaru.onrender.com/bundle/pre-dispute/d8fb129c0c0c78d05256/export.txt",
    "diligence_url": "https://velaru.onrender.com/diligence/velari"
  },
  {
    "named_entity": "LinkAudit Test",
    "slug": "linkaudit-test",
    "ai_use_case": "AI-assisted Pharma / Clinical Trials decisions",
    "vertical": "pharma",
    "risk_tier": "elevated",
    "external_validation": "Velaru independent receipt verification",
    "handler_receipt_lock": "https://velaru.onrender.com/r/58ddedd1974156453bc55daef6a9857d8570d56388becbb2a80bf5bac76b771b",
    "compliance_state": "grace_period",
    "asymmetry_grade": "A",
    "found_scripture_export": "https://velaru.onrender.com/bundle/pre-dispute/78aa6e3f3a84cf1a88c0/export.txt",
    "diligence_url": "https://velaru.onrender.com/diligence/linkaudit-test"
  },
  {
    "named_entity": "Link Audit Co",
    "slug": "link-audit-co",
    "ai_use_case": "AI-assisted Pharma / Clinical Trials decisions",
    "vertical": "pharma",
    "risk_tier": "elevated",
    "external_validation": "Velaru independent receipt verification",
    "handler_receipt_lock": "https://velaru.onrender.com/r/d00533b7b6c0495802b4250abd5c29f60bd9f2ad3fb141bba2d9a5afee5f5542",
    "compliance_state": "grace_period",
    "asymmetry_grade": "A",
    "found_scripture_export": "https://velaru.onrender.com/bundle/pre-dispute/fea572f3996c4b963779/export.txt",
    "diligence_url": "https://velaru.onrender.com/diligence/link-audit-co"
  }
]

EXHIBIT B — GOVERNANCE FRAMEWORK
{
  "framework": "Velaru Mandate Registry \u2014 Pharma / Clinical Trials",
  "exhibit_authority": "Switzerland FINMA AI Pack \u2014 21 CFR Part 11 Clinical AI Audit Pack",
  "regulatory_frameworks": [
    "FDA 21 CFR Part 11",
    "GCP ICH E6",
    "EU AI Act Annex III",
    "Revised FADP",
    "FINMA AI guidance",
    "Swiss AI policy"
  ],
  "standards_alignment": [
    "POSS-2",
    "DRP-1",
    "TCB",
    "FRE 707 pre-compliance",
    "ISO 42001"
  ],
  "human_oversight": "release clinical batch / report adverse event",
  "third_party_verification": "https://velaru.onrender.com/verify (operator-independent)",
  "data_lineage": "Hash-chained Ed25519 receipts; optional RFC3161 + external anchor",
  "mirror_trap": "Sponsors using vendor AI for protocol deviation detection \u2014 sponsor owns FDA finding, vendor owns nothing. \u00b7 Swiss reinsurance hub \u2014 Munich Re, Swiss Re need asymmetry data with Swiss privacy compliance.",
  "chain_integrity": {
    "depth": 360,
    "invariant_holds": true
  }
}

EXHIBIT D — DATA INPUTS & VALIDATION
{
  "data_validation_method": "Cryptographic receipt per AI decision; public verify without trusting deployer, vendor, or Velaru operator",
  "bias_testing_proxy": "Asymmetry score from live chain signals",
  "model_change_control": "Policy lock registry \u2014 criteria hash frozen pre-dispute",
  "logging_retention": "90-day pre-dispute window minimum; permanent verify permalinks",
  "external_validator": "Nisaba LLC / Velaru",
  "validator_independence": "Client-side Ed25519 verify; BYOK tri-receipt optional",
  "headline_stat": "21 CFR Part 11 already requires what Velaru does \u2014 not AI safety, compliance",
  "global_leaders_addressed": [
    "FDA",
    "Pfizer",
    "IQVIA",
    "Veeva",
    "EMA",
    "FINMA",
    "Swiss Re",
    "Munich Re"
  ]
}

MIRROR TRAP (regulatory insight)
Sponsors using vendor AI for protocol deviation detection — sponsor owns FDA finding, vendor owns nothing. · Swiss reinsurance hub — Munich Re, Swiss Re need asymmetry data with Swiss privacy compliance.

NERVE CARDS — WHY GLOBAL LEADERS CARE
[
  {
    "title": "483 observations",
    "body": "FDA inspection: show audit trail for AI-flagged deviation \u2014 altered records = criminal referral pattern.",
    "source": "vertical"
  },
  {
    "title": "ICH E6 GCP",
    "body": "AI-assisted monitoring must be in validation documentation \u2014 post-hoc PowerPoint fails.",
    "source": "vertical"
  },
  {
    "title": "Trial insurance",
    "body": "Clinical trial insurers now ask AI governance questionnaire \u2014 receipts beat questionnaires.",
    "source": "vertical"
  },
  {
    "title": "[Switzerland] Reinsurance capital",
    "body": "Geneva/Zurich reinsurers price AI risk \u2014 actuarial feed jurisdiction-scoped.",
    "source": "jurisdiction"
  },
  {
    "title": "[Switzerland] Banking secrecy",
    "body": "Swiss bank AI \u2014 FINMA documentation expectations exceed EU for trading AI.",
    "source": "jurisdiction"
  },
  {
    "title": "[Text / Chat] Modality hook",
    "body": "Baseline \u2014 all frameworks apply to text decisions.",
    "source": "modality"
  }
]

BOOK SUMMARY: {
  "total_insureds": 3,
  "compliant": 0,
  "grace_period": 3,
  "non_compliant": 0,
  "expired": 0,
  "not_enrolled": 0,
  "compliant_pct": 0.0
}

TAM / EXPOSURE: $200B+ pharma R&D · AI in trial design exploding
INSURANCE LINES: Product liability, Clinical trial E&O

DISCLAIMER: External validation evidence pack — not legal advice, not filed rate approval.